FEB 01, 2019 10:55 AM PST

Can Israeli Company Keep its Promise for a Cure For Cancer?

WRITTEN BY: Amy Loriaux

Accelerated Evolution Biotechnology, Ltd. (AEBI), an Israeli company led by CEO Dr. Ilan Morad, made some bold claims on January 29th, 2019, about its company's ability to cure cancer "within [a] year's time". This was stated by Dan Aridor, the company's Chairman of the Board. AEBI's technology is based on its new cancer-fighting technology and its ability to find potential targets using SoAP, a technique which uses viral-mediated gene transfer to infect cells.

Photo source: Adobe Shutterstock (used with permission)

The therapy then uses a multi-target toxin (MuTaTo) to find those infected cells (putative cancer cells) and kills them. This is, in effect, an anti-biotic for tumor cells, at least that is what Dan Aridor, the company's Chairman of the Board, said in The Jerusalem Post. The company has already been granted a US patent for AEBI's SoAP-based platform and has shown proof of concept using human epithelial carcinoma cells.

In essence, these promises are based solely on nonclinical results. The group has yet to publish their results in a peer-reviewed (the golden standard for authenticity) journal. Many oncologists are doubtful that the science will actually go anywhere, one spokesperson for Duke Health calling this a "non-story". Another researcher was quoted as stating “As someone with 10 years of molecular biology and medical experience, I strongly suspect the Israeli scientists…are completely misrepresenting their supposed discovery." He went on to call-out snake oil on the claim.

Photo source: UnSplash.com

Some scientists are very concerned that this could raise false hope in the estimated 1,735,350 people who were predicted to be diagnosed in 2018. Some researchers are even incensed. "I really think that it's really unfair and almost cruel to bandy about these likely to be false hopes to cancer patients," stated Dr. Benjamin Neel, the director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health. He went on to say, "When they present it for peer review and it's published in a respectable journal and we can look at it, then that will be another story". 

Aridor said AEBi does not publish in peer review papers. The company did give "detailed lectures" on its progress and findings in three Drug Discovery conferences in 2017 and 2018, and added it received "wonderful reviews." However, since these data are nonclinical, the company will need many more years of research and funding to be approved for use in the US. Pre-clinical animal trials, three phases of clinical trials, and much more data will have to be gathered. In essence, this technology will not be available, at least in the States, in one year's time.

Sources: http://www.aebi-bio.com/, www.6abc.com, Applied and Environmental Microbiology, The Jerusalem Post, www.LinkedIn.com, www.cancer.gov

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 28, 2021
Immunology
Cell Therapy Scrubs Tumors, Spares Transplanted Organs
SEP 28, 2021
Cell Therapy Scrubs Tumors, Spares Transplanted Organs
Hepatitis B infections have created a ‘silent epidemic’—infected people don’t display any sympto ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
JAN 17, 2022
Cancer
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
JAN 17, 2022
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
Immune checkpoint inhibitors (ICIs) have become a promising new treatment for advanced cancers, including melanoma. Immu ...
Loading Comments...